Core Viewpoint - Haohai Biological Technology has successfully expanded its product lines in the medical aesthetics and ophthalmology sectors, enhancing its global market presence and growth potential [2]. Group 1: Medical Aesthetics - Haohai's subsidiary Bioxis has successfully launched its Cytosial hyaluronic acid product in Europe, South America, and the Middle East, achieving sales in these regions [2]. Group 2: Ophthalmology - The company's core platform Contamac supplies approximately 17 million optical raw materials annually to contact lens and artificial lens manufacturers in over 70 countries worldwide [2]. - The establishment of these platforms is expected to continuously empower the global layout of the company's product lines, opening up broader development opportunities [2].

Core Viewpoint - The dialogue at the FBIF 2025 Food and Beverage Innovation Forum highlighted China Feihe's innovative research and product expansion strategy, focusing on a full age range from infants to the elderly, in response to market demands and demographic changes [1][2]. Group 1: Product Innovation and Development - China Feihe is currently the leading company in infant formula sales both domestically and globally, and is expanding its product offerings beyond infants to include children, youth, adults, and the elderly [1]. - The company is developing higher quality products that are closer to breast milk for infants, while also addressing the nutritional needs of the aging population in China [2]. Group 2: Research Initiatives - In 2022, China Feihe led a key research initiative under the Ministry of Science and Technology's "14th Five-Year Plan," aiming to establish the largest maternal and infant cohort study in China, with over 3,000 mother-infant pairs and more than 6,000 breast milk samples to analyze regional variations and their impact on child development [3]. Group 3: Raw Material Production - China Feihe has made significant advancements in domestic production of essential raw materials for infant formula, such as lactoferrin and whey protein, to reduce reliance on imports, especially in light of current trade tensions [4]. Group 4: Global Market Strategy - The company has established a production facility in Canada to cater to the North American market, designing products based on local breast milk characteristics, and is also exploring opportunities in Southeast Asia through local collaborations [5]. - Future plans include expanding infant products internationally while aligning research efforts with local scientists to better understand regional nutritional needs [6].